Drug Trial Radar · NCT03105375
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Feb 21, 2017
Primary completion
Oct 12, 2017
Study completion Oct 12, 2017
Sponsor
- Lead sponsor
- Cinclus Pharma Holding ABIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2017
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
Conditions
- Healthy Volunteers
Interventions
Single ascending dose of X842Drug
Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
Multiple ascending dose of X842Drug
Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
LosecDrug
Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.Time frame: Five weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Consultants
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.